CuraGen Corporation to Discuss Fourth Quarter and Year End 2007 Financial Results Via Conference Call on January 31, 2008

BRANFORD, Conn., Jan. 24 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call to discuss CuraGen's fourth quarter and year end 2007 financial results at 11:00 a.m. Eastern Standard Time on Thursday, January 31, 2008. A press release outlining 2007 results and 2008 financial guidance for CuraGen will be issued prior to the call.

http://www.curagen.com

A replay of the conference call will be available starting at 2:00 p.m. Eastern Standard Time on Thursday, January 31, 2008 through Saturday, March 1, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 31898426. An archive of the webcast will also be available for 30 days at http://www.curagen.com.

About CuraGen

CuraGen Corporation is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com.

gschulman@curagen.com

CONTACT: Glenn Schulman, PharmD, Director of Investor Relations of CuraGen
Corporation, +1-888-436-6642, gschulman@curagen.com

Web site: http://www.curagen.com/

Back to news